LUND, Sweden, June 18, 2019 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX),
a biotechnology company developing antibody-based
pharmaceuticals for tumor-directed immunotherapy, today announced
that the company has submitted clinical trial authorization (CTA)
application to initiate a Phase I study of its fully owned 4-1BB
antibody ATOR-1017 for the treatment of metastasizing cancer.
ATOR-1017 is an immunostimulatory IgG4 antibody that activates
tumor-specific T cells and NK cells through the costimulatory
receptor 4-1BB. T cells and NK cells have the capacity to detect
and kill tumor cells, making 4-1BB a particularly attractive target
for cancer immunotherapy.
ATOR-1017 has a unique profile related to the fact that its
immunostimulatory function is stronger in areas where immune cells
are abundant, notably in tumors. This creates an opportunity for a
strong immune activation, while minimizing side effects for the
patient.
The upcoming Phase I study will be a first-in-human, dose
escalation study in patients with advanced cancer. It will be
conducted at 3 sites in Sweden and
will enroll up to 50 patients. The primary objective of the study
is to assess the safety and tolerability of ATOR-1017 and to
determine the recommended dose for the subsequent Phase II
studies.
"We look forward to begin patient recruitment following approval
of the ATOR-1017 application by regulators. Our data support its
potential to generate a potent and long-lasting immune response or
even to induce immunity to cancer, while minimizing side effects
through tumor-directed immune activation. This will be the third of
our drug candidates to enter the clinic, as we continue to make
great progress developing the next generation of cancer
immunotherapies", said Per Norlén, CEO of Alligator Bioscience.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 4:15 p.m. CEST on June 18,
2019.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes five lead clinical and
preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017,
ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for
global development and commercialization.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-submits-clinical-trial-application-for-ator-1017,c2840277
The following files are available for download:
https://mb.cision.com/Main/12681/2840277/1064854.pdf
|
Alligator Bioscience
submits clinical trial application for ATOR-1017
|